{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:21:57Z","timestamp":1782962517907,"version":"3.54.5"},"reference-count":55,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:00:00Z","timestamp":1646438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2017YFB0202600"],"award-info":[{"award-number":["2017YFB0202600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["XDA12020368"],"award-info":[{"award-number":["XDA12020368"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802496"],"award-info":[{"award-number":["81802496"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["18YF1402700"],"award-info":[{"award-number":["18YF1402700"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High Technology Research and Development Program of China","award":["2014AA020611"],"award-info":[{"award-number":["2014AA020611"]}]},{"DOI":"10.13039\/501100014219","name":"National Science Fund for Distinguished Young Scholars","doi-asserted-by":"publisher","award":["81725011"],"award-info":[{"award-number":["81725011"]}],"id":[{"id":"10.13039\/501100014219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Growth hormone pituitary adenoma (GHPA), a major subtype of pituitary adenoma (PA), can lead to progressive somatic disfigurement, multiple complications, and even increased mortality. The efficacy of current treatments is limited; thus, a novel pharmacological treatment is urgently needed. As a histone acetyltransferase (HAT) coactivator, p300 can regulate the transcription of several genes that are crucial for PA tumorigenesis and progression. However, the role of p300 and its catalytic inhibitor in GHPA is still unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We aimed to identify the expression of p300 in GHPA and in normal pituitary glands.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The expression of p300 was detected in GHPA and normal pituitary tissues. Genetic knockdown was performed by siRNA. The efficacy of the p300 inhibitor A-485 in the cell cycle, proliferation, apoptosis, and hormone secretion was investigated by flow cytometry, ELISAs, Western blotting, and qRT-PCR. RNA sequencing, bioinformatic analysis, and subsequent validation experiments were performed to reveal the potential biological mechanism of A-485.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>High expression of p300 was found in GHPA tissues compared with normal pituitary tissues. Knockdown of p300 inhibited cell proliferation and clone formation. Treatment with A-485 suppressed cell growth and inhibited the secretion of GH in vitro and in vivo. Further mechanistic studies showed that A-485 could downregulate the expression or activity of several oncogenes, such as genes in the Pttg1, c-Myc, cAMP and PI3K\/AKT\/mTOR signaling pathways, which are crucial for PA tumorigenesis and progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings demonstrate that inhibition of HAT p300 by its selective inhibitor A-485 is a promising therapy for GHPA.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgac128","type":"journal-article","created":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T18:09:46Z","timestamp":1646503786000},"page":"e2291-e2300","source":"Crossref","is-referenced-by-count":32,"title":["The p300 Inhibitor A-485 Exerts Antitumor Activity in Growth Hormone Pituitary Adenoma"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1226-5658","authenticated-orcid":false,"given":"Chenxing","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[{"name":"Hospital & Institute of Obstetrics and Gynecology, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, China"},{"name":"Drug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhang","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Han","sequence":"additional","affiliation":[{"name":"Drug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yu","sequence":"additional","affiliation":[{"name":"Drug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidan","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, China"},{"name":"Shanghai Key laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, China"},{"name":"Shanghai Key laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, China"},{"name":"Shanghai Key laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, China"},{"name":"Shanghai Key laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijin","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Luo","sequence":"additional","affiliation":[{"name":"Drug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6492-9511","authenticated-orcid":false,"given":"Zhiyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-8035","authenticated-orcid":false,"given":"Bing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"},{"name":"School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, UCAS, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-3993","authenticated-orcid":false,"given":"Zhao","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, China"},{"name":"Shanghai Key laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, China"},{"name":"Shanghai Key laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China"},{"name":"State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai, China"},{"name":"National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,3,5]]},"reference":[{"key":"2022051722351678800_CIT0001","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nou223","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro Oncol"},{"issue":"5","key":"2022051722351678800_CIT0002","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1530\/EJE-15-0189","article-title":"The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study","volume":"173","author":"Agustsson","year":"2015","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2022051722351678800_CIT0003","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1530\/EJE-16-0117","article-title":"Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study","volume":"175","author":"Dal","year":"2016","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2022051722351678800_CIT0004","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11102-015-0655-4","article-title":"The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013","volume":"18","author":"Hoskuldsdottir","year":"2015","journal-title":"Pituitary"},{"issue":"2","key":"2022051722351678800_CIT0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1530\/EJE-12-0084","article-title":"Predictors of morbidity and mortality in acromegaly: an Italian survey","volume":"167","author":"Arosio","year":"2012","journal-title":"Eur J Endocrinol."},{"issue":"5","key":"2022051722351678800_CIT0006","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"2022051722351678800_CIT0007","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2217\/cns.15.21","article-title":"Pituitary adenomas: historical perspective, surgical management and future direction. review","volume":"4","author":"Theodros","year":"2015","journal-title":"CNS Oncology"},{"issue":"1","key":"2022051722351678800_CIT0008","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers."},{"issue":"3","key":"2022051722351678800_CIT0009","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/er.2009-0033","article-title":"Mortality in patients with pituitary disease","volume":"31","author":"Sherlock","year":"2010","journal-title":"Endocr Rev."},{"issue":"6","key":"2022051722351678800_CIT0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1530\/ERC-16-0106","article-title":"Mortality in acromegaly: a 20-year follow-up study","volume":"23","author":"Ritvonen","year":"2016","journal-title":"Endocr Relat Cancer."},{"issue":"11","key":"2022051722351678800_CIT0011","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an Endocrine Society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2022051722351678800_CIT0012","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol."},{"issue":"11","key":"2022051722351678800_CIT0013","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s00701-017-3318-6","article-title":"Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications","volume":"159","author":"Chen","year":"2017","journal-title":"Acta Neurochir (Wien)"},{"issue":"8","key":"2022051722351678800_CIT0014","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1210\/jc.2013-1036","article-title":"Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission","volume":"98","author":"Starke","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"2022051722351678800_CIT0015","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.wneu.2017.04.141","article-title":"Outcome of Endoscopic Transsphenoidal Surgery for Acromegaly","volume":"104","author":"Kim","year":"2017","journal-title":"World Neurosurg"},{"issue":"2","key":"2022051722351678800_CIT0016","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/neuros\/nyx020","article-title":"Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors","volume":"81","author":"Babu","year":"2017","journal-title":"Neurosurgery"},{"issue":"5","key":"2022051722351678800_CIT0017","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/cen.12207","article-title":"Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists","volume":"79","author":"Howlett","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2022051722351678800_CIT0018","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11102-009-0191-1","article-title":"Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension","volume":"13","author":"Melmed","year":"2010","journal-title":"Pituitary"},{"issue":"6","key":"2022051722351678800_CIT0019","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/cen.12440","article-title":"Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study","volume":"81","author":"Sesmilo","year":"2014","journal-title":"Clinical Endocrinology"},{"issue":"10","key":"2022051722351678800_CIT0020","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1210\/jc.2014-2032","article-title":"Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly","volume":"99","author":"Neggers","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022051722351678800_CIT0021","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11102-016-0778-2","article-title":"Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas","volume":"20","author":"Ben-Shlomo","year":"2017","journal-title":"Pituitary"},{"issue":"3","key":"2022051722351678800_CIT0022","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","article-title":"Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary"},{"issue":"8","key":"2022051722351678800_CIT0023","doi-asserted-by":"crossref","first-page":"943","DOI":"10.4158\/EP14574.OR","article-title":"Radiotherapy Versus Radiosurgery in Treating Patients with Acromegaly: A Systematic Review and Meta-Analysis","volume":"21","author":"Abu Dabrh","year":"2015","journal-title":"Endocr Pract."},{"issue":"1","key":"2022051722351678800_CIT0024","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11102-016-0783-5","article-title":"Updates in outcomes of stereotactic radiation therapy in acromegaly","volume":"20","author":"Gheorghiu","year":"2017","journal-title":"Pituitary"},{"issue":"6","key":"2022051722351678800_CIT0025","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2826.2011.02129.x","article-title":"Histone acetylation patterns of typical and atypical pituitary adenomas indicate epigenetic shift of these tumours","volume":"23","author":"Ebrahimi","year":"2011","journal-title":"J Neuroendocrinol."},{"issue":"20","key":"2022051722351678800_CIT0026","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1101\/gad.1444606","article-title":"Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease","volume":"20","author":"Bilodeau","year":"2006","journal-title":"Genes Dev."},{"issue":"12","key":"2022051722351678800_CIT0027","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cbin.10834","article-title":"Histone deacetylase 11 suppresses p53 expression in pituitary tumor cells","volume":"41","author":"Wang","year":"2017","journal-title":"Cell Biol Int."},{"issue":"1","key":"2022051722351678800_CIT0028","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/epi.5.1.10449","article-title":"Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases","volume":"5","author":"Bedford","year":"2010","journal-title":"Epigenetics"},{"issue":"24","key":"2022051722351678800_CIT0029","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1038\/sj.onc.1207118","article-title":"p300\/CBP and cancer","volume":"23","author":"Iyer","year":"2004","journal-title":"Oncogene"},{"issue":"22","key":"2022051722351678800_CIT0030","first-page":"7638","article-title":"p300 in prostate cancer proliferation and progression","volume":"63","author":"Debes","year":"2003","journal-title":"Cancer Res."},{"key":"2022051722351678800_CIT0031","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1479-5876-9-5","article-title":"High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma","volume":"9","author":"Li","year":"2011","journal-title":"J Transl Med."},{"key":"2022051722351678800_CIT0032","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1479-5876-10-110","article-title":"High expression of p300 is linked to aggressive features and poor prognosis of nasopharyngeal carcinoma","volume":"10","author":"Liao","year":"2012","journal-title":"J Transl Med."},{"issue":"6","key":"2022051722351678800_CIT0033","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1673-8527(08)60122-8","article-title":"Histone acetyltransferase p300 regulates the expression of human pituitary tumor transforming gene (hPTTG)","volume":"36","author":"Li","year":"2009","journal-title":"J Genet Genomics."},{"issue":"4","key":"2022051722351678800_CIT0034","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/2159-8290.CD-15-0754","article-title":"Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression","volume":"6","author":"Ogiwara","year":"2016","journal-title":"Cancer Discov"},{"issue":"5","key":"2022051722351678800_CIT0035","doi-asserted-by":"crossref","first-page":"H1255","DOI":"10.1152\/ajpheart.01266.2008","article-title":"CBP and p300 are essential for renin cell identity and morphological integrity of the kidney","volume":"296","author":"Gomez","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"4","key":"2022051722351678800_CIT0036","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1210\/mend.11.4.9911","article-title":"Isolation and characterization of a pituitary tumor-transforming gene (PTTG)","volume":"11","author":"Pei","year":"1997","journal-title":"Mol Endocrinol."},{"issue":"4","key":"2022051722351678800_CIT0037","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3892\/mmr.2017.6169","article-title":"Increased betacatenin and c-myc expression predict aggressive growth of non-functioning pituitary adenomas: An assessment using a tissue microarray-based approach","volume":"15","author":"Liu","year":"2017","journal-title":"Mol Med Rep."},{"issue":"11","key":"2022051722351678800_CIT0038","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1172\/JCI138540","article-title":"DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas","volume":"130","author":"Ben-Shlomo","year":"2020","journal-title":"J Clin Invest."},{"issue":"7674","key":"2022051722351678800_CIT0039","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"issue":"1","key":"2022051722351678800_CIT0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cell.2018.04.033","article-title":"Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP\/p300 Acetylome","volume":"174","author":"Weinert","year":"2018","journal-title":"Cell"},{"key":"2022051722351678800_CIT0041","article-title":"A-485 GHPA supplementary materials","author":"Chenxing","year":"2022","journal-title":"figshare"},{"issue":"6","key":"2022051722351678800_CIT0042","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1039\/C7MD00083A","article-title":"Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay","volume":"8","author":"Chen","year":"2017","journal-title":"Medchemcomm."},{"issue":"9","key":"2022051722351678800_CIT0043","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1507\/endocrj.EJ16-0175","article-title":"The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly","volume":"63","author":"Wang","year":"2016","journal-title":"Endocr J."},{"issue":"3","key":"2022051722351678800_CIT0044","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/onc.2015.92","article-title":"The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia","volume":"35","author":"Giotopoulos","year":"2016","journal-title":"Oncogene."},{"issue":"3","key":"2022051722351678800_CIT0045","doi-asserted-by":"crossref","first-page":"e90396","DOI":"10.1371\/journal.pone.0090396","article-title":"Correlations of pituitary tumor transforming gene expression with human pituitary adenomas: a meta-analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One."},{"issue":"1","key":"2022051722351678800_CIT0046","first-page":"253","article-title":"c-myc, c-fos, and c-myb gene expression in human pituitary adenomas","volume":"79","author":"Woloschak","year":"1994","journal-title":"J Clin Endocrinol Metab."},{"key":"2022051722351678800_CIT0047","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mce.2017.08.006","article-title":"Cyclic 3\u2019,5\u2019-adenosine monophosphate (cAMP) signaling in the anterior pituitary gland in health and disease","volume":"463","author":"Hernandez-Ramirez","year":"2018","journal-title":"Mol Cell Endocrinol."},{"issue":"4","key":"2022051722351678800_CIT0048","doi-asserted-by":"crossref","first-page":"R331","DOI":"10.1530\/ERC-14-0188","article-title":"The PI3K\/AKT\/mTOR pathway in the pathophysiology and treatment of pituitary adenomas","volume":"21","author":"Monsalves","year":"2014","journal-title":"Endocr Relat Cancer."},{"issue":"1","key":"2022051722351678800_CIT0049","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12022-012-9230-y","article-title":"mTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features","volume":"24","author":"Sajjad","year":"2013","journal-title":"Endocr Pathol."},{"issue":"2","key":"2022051722351678800_CIT0050","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1677\/erc.1.00949","article-title":"Enhanced protein kinase B\/Akt signalling in pituitary tumours","volume":"12","author":"Musat","year":"2005","journal-title":"Endocr Relat Cancer."},{"issue":"1","key":"2022051722351678800_CIT0051","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12022-012-9230-y","article-title":"mTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features","volume":"24","author":"Sajjad","year":"2013","journal-title":"Endocr Pathol."},{"issue":"2","key":"2022051722351678800_CIT0052","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s12020-017-1432-0","article-title":"PI3K\/Akt\/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line","volume":"60","author":"Di Pasquale","year":"2018","journal-title":"Endocrine."},{"issue":"1","key":"2022051722351678800_CIT0053","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-015-1895-x","article-title":"Specific inhibition of mTOR pathway induces anti-proliferative effect and decreases the hormone secretion in cultured pituitary adenoma cells","volume":"125","author":"Xie","year":"2015","journal-title":"J Neurooncol."},{"issue":"3","key":"2022051722351678800_CIT0054","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1677\/ERC-08-0269","article-title":"Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro","volume":"16","author":"Gorshtein","year":"2009","journal-title":"Endocr Relat Cancer."},{"issue":"3","key":"2022051722351678800_CIT0055","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1210\/en.2012-1908","article-title":"Inhibition of PI3K\/AKT\/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice","volume":"154","author":"Dai","year":"2013","journal-title":"Endocrinology."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac128\/43142810\/dgac128.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/6\/e2291\/43739737\/dgac128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/6\/e2291\/43739737\/dgac128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T12:48:34Z","timestamp":1700311714000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/6\/e2291\/6542975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,5]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3,5]]},"published-print":{"date-parts":[[2022,5,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac128","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,3,5]]}}}